Is Eligibility for a Chemotherapy Protocol a Good Prognostic Factor for Invasive Bladder Cancer After Radical Cystectomy?
- 15 October 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (20), 4103-4108
- https://doi.org/10.1200/jco.2004.04.127
Abstract
Purpose To assess whether eligibility to an adjuvant chemotherapy protocol in itself represents a good prognostic factor after radical cystectomy for bladder cancer. Patients and Methods Between April 1984 and May 1989, our institution entered 35 patients with invasive bladder cancer into the Swiss Group for Clinical and Epidemiological Cancer Research (SAKK) study 09/84. They were randomly assigned to either observation or three postoperative courses of cisplatin monotherapy after cystectomy. This study had a negative result. The outcome of these 35 patients (protocol group) was compared with an age- and tumor-stage–matched cohort (matched group; n = 35) who also underwent cystectomy during the same period, but were not entered into the SAKK study, as well as the remaining 57 patients treated during the study period for the same indication (remaining group). Results Median overall survival decreased from 76.3 months in the protocol group to 52.1 months in the matched group and to 20.3 months in the remaining group. The respective times of median recurrence-free survival were 67.2, 16.0, and 9.4 months. Tumor progression occurred in 46% of the protocol group compared with 69% in the matched group and 65% in the remaining group (P < .05). Cancer-related death was noted in 40% of the protocol group, 57% in the matched group, and 56% in the remaining group. Conclusion These data suggest that being willing and fit enough for a chemotherapy protocol is a good prognostic factor for invasive bladder cancer. This eligibility bias emphasizes the need for prospective, randomized trials, and indicates that single-group studies using historical or matched controls have to be interpreted with caution.Keywords
This publication has 15 references indexed in Scilit:
- Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant TherapyJournal of Clinical Oncology, 2003
- Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly ProgramControlled Clinical Trials, 1999
- Consecutive screening and enrollment in clinical trials: The way to representative patient samples?Journal of Cardiac Failure, 1998
- Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe?Journal of Clinical Oncology, 1997
- Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.Journal of Clinical Oncology, 1997
- Historical control bias: adjuvant chemotherapy in esophageal cancerDiseases of the Esophagus, 1997
- Influence of selection bias on dose-time analysis: a theoretical investigationRadiotherapy and Oncology, 1996
- Adjuvant Cisplatin Chemotherapy Following Cystectomy for Bladder Cancer: Results of a Prospective Randomized TrialJournal of Urology, 1994
- Selection bias in clinical trails of anaplastic gliomaAnnals of Neurology, 1989
- Age as a criterion for eligibility in a lung cancer clinical trialAmerican Journal of Clinical Oncology, 1982